The study found gender specificity in Alzheimer's therapy

In a recent study published in Science Signaling, an international team of researchers led by the University of Ottawa in Canada found that a specific treatment for Alzheimer's was effective in male mice and not in female mice.
the study highlights the fundamental gender differences between the underlying mechanisms of Alzheimer's disease for a particular treatment and provides a window into the pathophysiology of the disease and the effectiveness of targeted therapy.
study, researchers treated female and male mice with Alzheimer's disease.
the drug selectively blocks the metabolic glutamate lice 5 (mGluR5), which regulates memory and learning.
Then the researchers assessed the recovery effect of memory defects in post-treatment mice and their differences in sex, and also tested whether the combination of toxic β-amyloid protein and mGluR5 was different between female and male mice and the human brain.
(β amyloid) is present in the brains of Alzheimer's patients and is a feature of the disease.
"We found that at least one promising Alzheimer's treatment was effective in reversing disease in male mice, but not in female mice," said lead author Dr Khaled Abdelrahman of the University of Ottawa and the Institute of Brain Intelligence in the Department of Cell and Molecular Medicine at the Ottawa School of Medicine.
is important for the future development and clinical trial design of Alzheimer's drugs.
, the researchers confirmed the findings using posthumous brain tissue from male and female donors.
these selective differences may apply to many drugs on the market or during clinical trials.
many drug candidates may have different effects between different genders, we need to be extra cautious in our future clinical trial designs," said Abdelrahman, a research institute.
not all drugs that work for men are also effective for women, and vice versa.
also changed the way clinical trial data are evaluated and the need to disaggregate by sex.
importantly, the study defined a previously unknown difference in the biophysical properties of glutamate-type lithum 5, an important subject in the brain that regulates memory and learning.
, Abdelrahman added, "As a pharmacist, I have seen many patients struggle with Alzheimer's disease and ineffective treatment in practice."
this prompted me to try to understand the mechanisms that cause the disease in order to adopt more effective treatments.
”(）